Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA~The subject must satisfy all the following criteria to be eligible for the study:~1. Signed informed consent form (ICF)~2. Aged 18 to 35 years~3. Long term resident of study site (living there for at least 4 years)~4. Willingness to remain resident in the village and to abstain from travel for prolonged periods during the study~5. Willingness to undergo an HIV test and other tests needed for determining exclusion. (In case of a positive test, the clinician will issue a referral letter to the participant to guide him/her to HIV specialist care for appropriate management and follow up).~6. Willingness to take a curative anti-malarial regimen when prescribed by the investigator~7. Willingness to provide blood for safety data.~8. For females: agreement to use reliable contraception (in the setting where this trial takes place documented depot injection of contraceptives, surgical sterilization ; or an implanted device (all with written evidence provided by an appropriately trained physician) is considered reliable contraception) for the duration of the vaccination phase (i.e., from 1 month prior to first vaccination until 1 month after last vaccination)~9. For females: negative pregnancy test at screening and before each vaccination; women found pregnant will not be given subsequent doses but will be followed up for safety reasons~EXCLUSION CRITERIA~1. Use of antimalarials (other than that prescribed by the investigator) or systemic antibiotics with known antimalarial activity within 30 days prior to the first vaccine dose (e.g. Trimethoprim-Sulfamethoxazole, Doxycycline, Tetracycline, Clindamycin, Erythromycin, Fluoroquinolones, or Azithromycin)~2. Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period~3. Prior receipt of a malaria vaccine candidate~4. Recurrent, severe infections other than malaria, and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)~5. Use of immunoglobulins or blood products within 3 months prior to enrolment~6. A history of allergic disease or significant reactions against mosquito bites~7. Known allergies or contraindications against Artemether/Lumefantrine, or~   Atovaquone/Proguanil, such as:~  1. Concurrent medication with Neuroleptics, Antidepressants (i.e., Imipramine, Amitryptilline, Clomipramine and others), Drugs used to treat tuberculosis, including Rifampicin and Rifabutine, Macrolide antibiotics (i.e., Erythromycin, Clarithromycin, Azithromycin, Roxitromycin), Fluoroquinolones (i.e., Ciprofloxacin, Moxifloxacin, Levofloxacin), Antimykotics (i.e., Ketoconazole, Itraconazole), Cimetidine, Class IA and class III antiarrhythmics (i.e., Quinidine, Ajmalin, Disopyramid, Amiodaron, Sotalol), Flecainid, Metoprolol, Cisaprid, Terfenadin, Astemizole, and Metoclopramide~  2. Renal impairment~  3. Symptoms of low potassium, and/or low magnesium~  4. A family history of sudden cardiac death, which in the opinion of the investigator was caused by a pre-existing arrhythmia~  5. Known diagnosis or family history of long QT syndrome~  6. Heart disease (i.e., heart failure, arrhythmias)~8. History of cancer (except basal cell carcinoma)~9. History of serious psychiatric condition that may affect participation in the study~10. If female: currently pregnant, lactating and / or breast-feeding~11. Any other serious chronic illness requiring hospital specialist supervision such as diabetes mellitus type 2.~12. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 60 g per day~13. Suspected or known injecting drug abuse in the 5 years preceding enrolment~14. Any confirmed or suspected immunosuppressive or immune modulating disorder (i.e., asplenia, lupus, rheumatoid arthritis, vasculitis, sclerodermia, diabetes mellitus)~15. Hematuria, proteinuria, glucosuria as detected by urine dip stick above the levels defined in Appendix F~16. Any clinically significant abnormalities on a 12 lead ECG~17. Seropositive for Hepatitis B surface antigen (HBsAg)~18. Seropositive for Hepatitis C virus (antibodies to HCV)~19. Seropositive for HIV~20. Seropositive for Syphilis~21. Sickle cell trait carriage or sickle cell disease~22. Any clinically significant abnormal finding on biochemistry or hematology blood tests, urinalysis or clinical examination~23. Any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the subject because of participation in the study, affect the ability of the subject to participate in the study or impair interpretation of the study data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Pilot Safety Group- 135000 PfSPZ + 270000 PfSPZ; staggered at Day 0 and 2 weeks
- Group 4 (Type: ACTIVE_COMPARATOR): Group to start at week 4 after Group 1 is deemed safe - 5 immunizations of 270000 PfSPZ at weeks 4, 8, 12, 16 and 24
- Group 5 (Type: PLACEBO_COMPARATOR): Group to receive placebo at same points as Group 4 - 5 immunizations of normal saline at weeks 4, 8, 12, 16 and 24

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete